HARVONI – Buy Online Harvoni from India Exporters | Price Harvoni

HARVONI Tablets – Chawla Medicos has been setting benchmarks of success in the market as a prominent organization engaged in offering HARVONI Tablets. These tablets are used in combination with other medical products for the treatment of chronic hepatitis C (CHC) in adults. We source HARVONI Tablets from the most authentic vendors of the market. Packed in quality approved materials, these tablets are available in different quantity packaging options. Chawla Medicos offer Online Buy HARVONI from India at reasonable prices to clients. 


Harvoni Trade Information

Minimum Order Quantity 1.00 Unit of Measure Piece/Pieces
Payment Terms Cash Advance (CA), Paypal, Others Supply Ability On Order Per Week
Delivery Time 7-15 Days Sample Policy Within a certain price range free samples are available
Packaging Details Carton Boxes Packaging Main Export Market(s) Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Africa
Main Domestic Market All India Certifications Certified Products.
Export Countries Details: Countries: Russsia, Ukrain, Korea, Ajbakistan, Romania, Kajistan, Poland, USA, India, Philipines & China

Prices of Harvoni Tablets Distributors, Traders, Exporters & Suppliers

Harvoni is a fixed-dose combination tablet containing ledipasvir and sofosbuvir for oral administration. Ledipasvir is an HCV NS5A inhibitor and sofosbuvir is a nucleotide analog inhibitor of HCV NS5B polymerase.

Doses & Administration

Each tablet contains 90 mg ledipasvir and 400 mg sofosbuvir. Tablets include the following inactive ingredients: colloidal silicon dioxide, copovidone, croscarmellose sodium, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. These tablets are film-coated with a coating material containing the following inactive ingredients: FD&C yellow #6/sunset yellow FCF aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.

It is indicated with or without ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection.

Side Effects:

If Harvoni is administered with ribavirin, refer to the prescribing information for ribavirin for a description of ribavirin-associated adverse reactions. The safety assessment was based on pooled data from three randomized, open-label Phase 3 clinical trials (ION-3, ION-1 and ION-2) of subjects with genotype 1 HCV with compensated liver disease (with and without cirrhosis) including 215, 539, and 326 subjects who received once daily by mouth for 8, 12 and 24 weeks, respectively.

The proportion of subjects who permanently discontinued treatment due to adverse events was 0%, less than 1%, and 1% for subjects receiving these tablets for 8, 12, and 24 weeks, respectively.

The most common adverse reactions (at least 10%) were fatigue and headache in subjects treated with 8, 12, or 24 weeks of Harvoni.

Potential For Drug Interaction

As Harvoni contains ledipasvir and sofosbuvir, any interactions that have been identified with these agents individually may occur with tablets.

After oral administration of tablets, sofosbuvir is rapidly absorbed and subject to extensive first-pass hepatic extraction. In clinical pharmacology studies, both sofosbuvir and the inactive metabolite GS-331007 were monitored for purposes of pharmacokinetic analyses. Ledipasvir is an inhibitor of the drug transporters P-gp and breast cancer resistance protein (BCRP) and may increase intestinal absorption of coadministered substrates for these transporters.

Ledipasvir and sofosbuvir are substrates of drug transporters P-gp and BCRP while GS-331007 is not. P-gp inducers (e.g., rifampin or St. John’s wort) may decrease ledipasvir and sofosbuvir plasma concentrations, leading to reduced therapeutic effect of Harvoni, and the use with P-gp inducers is not recommended with Harvoni.


There are no reviews yet.

Be the first to review “Harvoni”